

A Presentation to the 11th Annual Value-Based Payment and P4P Summit



CUT TO THE CHASE!



- Medicare: world's largest VBID/VBP laboratory
 - Medicaid, ObamaCare, large commercial purchasers follow 3-5 years later
- Next frontier: social determinants
- Star Ratings drive the market, and bar is rising
- "A Darwinian moment" for payers, providers and vendors, especially PBMs

VBID LESSONS FROM MEDICARE ADVANTAGE/PART D

- 1. All healthcare is local. Start by tailoring best practices to a specific panel of members
- Addressing social determinants must be first priority before quality measures can improve
- 3. Reduce cost sharing for specific drugs/classes, e.g., oral agents, insulins
- 4. Exempt specific drugs/classes from cost sharing in the "donut hole": target those patients with high annual drug spending for greatest benefit
- 5. Reduce cost sharing for enrollees with chronic conditions
- Incentivize members to participate in medication therapy management programs (MTM)
- Create multi-tier cost sharing arrangements for high-value providers to encourage their use
- 8. Team-based proactivity is key must be ahead of the curve on quality measures and hard-wired into workflow

COST SHARING = BARRIER TO ACCESS

- Increases in member costsharing leads to a reduction in the use of essential services, worsening health disparities, exacerbating overall costs.
- Effects worse among lowincome individuals and beneficiaries with chronic illness


Business Day TECHNOLOGY SCIENCE HEALTH SPORTS OPINION When a Co-Pay Gets in the Way of Health ECONOMISTS specialize in pointing out unpleasent trade-offs—a skill that is on full display in the health care debate. B. Enlarge This Image We want patients to receive the best care available. We also want consumers to pay less. And we don't want to bankrupt the government or private insurers, Something must give. The debate centers on how to make these trade-offs, and who gets to make them. The stakes are high, and the attractive work. It's no surprise, then, that the conversation is so heated. matter how necessary, putting human


The New York Cimes


Source: Goldman D. JAMA. 2007;298(1):61–9. Trivedi A. NEJM. 2008;358:375-383. Trivedi A. NEJM. 2010;362(4):320-8.. Chernew M. J Gen Intern Med 23(8):1131–6.

IN MA, HIGHER OOP COSTS = WORSE HEALTH AND DISPARITIES, INCREASED COSTS

Out of Pocket Expenditures for MA Beneficiaries, 2011-2015







Source: Univ. of MI Center for V-BID, 2016

VBID CAN ADDRESS SYSTEMIC PROBLEMS


Members, Providers and Vendors Can All "Follow the Money"

Category	Sources	Estimate of Excess Costs	% of Waste	% of Total
Unnecessary Services	 Overuse beyond evidence-established levels Discretionary use beyond benchmarks Unnecessary choice of higher-cost services 	\$210 billion	27%	9.15%
Inefficiently Delivered Services	 Mistakes, errors, preventable complications Care fragmentation Unnecessary use of higher-cost providers Operational inefficiencies at care delivery sites 	\$130 billion	17%	5.66%
Excess Admin Costs	 Insurance paperwork costs beyond benchmarks Insurers' administrative inefficiencies Inefficiencies due to care documentation requirements 	\$190 billion	25%	8.28%
Prices that are too high	 Service prices beyond competitive benchmarks Product prices beyond competitive benchmarks 	\$105 billion	14%	4.58%
Missed Prevention Opportunities	Primary preventionSecondary preventionTertiary prevention	\$55 billion	7%	2.40%
Fraud	All sources – payers, clinicians, patients	\$75 billion	10%	3.27%
	Total	\$765 billion		33.33%

SOURCE: "Best Care at Lower Cost: The Path to Continuously Learning Health Care in America." Institute of Medicine (2013)


APPLYING V-BID TO SPECIALTY PHARMA

- Impose no more than modest cost-sharing on high-value services
- Reduce cost-sharing in accordance with patient- or disease-specific characteristics
- Relieve patients from high costsharing after failure on a different medication
- Use cost-sharing to encourage patients to select high-performing providers and settings



VBP LESSONS FROM MEDICARE ADVANTAGE/PART D


Value-Based Payment Models in Medicare:



VBP LESSONS FROM MEDICARE ADVANTAGE/PART D

Revenue Optimization Efforts Are Core Drivers Of MA VBP Activity

Percentage of respondents who replied "Important" or "Extremely important" when asked how they would rate the importance of each factor on their value-based strategy in MA



Source: Deloitte Center for Health Solutions, 2015 Study of Medicare Advantage Health Plans and Providers

STAR RATINGS DRIVE THE MARKET

Star Rating	Complaints/ 1,000	% Disenroll Annually
**	0.91	21.5%
* * ½	0.55	17.48%
***	0.42	14.79%
***1/2	0.33	9.27%
****	0.22	6.92%
****1/2	0.15	4.89%
****	0.16	1.91%

- Medicaid, ObamaCare already following MA approach
- Medicare Advantage plans beat commercial in HEDIS
- <4-Star plans "circling the toilet bowl"
- ≤3-Star plans "dead men walking"
- .5 Star = ~ \$15-\$50 PMPM

ACHIEVING THE GOAL

2016

2014

3.84

Final Year of Star Ratings Demo 2015

AVG STAR RATING

3.92

40% of MA-PDs earned ≥4 Stars

60% of MA-PD enrollees are in contracts with ≥4 Stars

AVG STAR RATING

4.03

49% of MA-PDs (179 contracts) earned ≥4 Stars

71% of MA-PD enrollees are in contracts with ≥4 Stars

ACHIEVING THE GOAL

2016

2014

3.84

Final Year of Star Ratings

BUT.....

- 369 plans were rated in 2016.188 more are on the chase.

2015

AVG STAR RATING

3.92

40% of MA-PDs earned ≥4 Stars

60% of MA-PD enrollees are in contracts with ≥4 Stars


AVG STAR RATING

4.03

49% of MA-PDs (179 contracts) earned ≥4 Stars

71% of MA-PD enrollees are in contracts with ≥4 Stars

THE GAME GETS TOUGHER




STAR RATINGS IN 2016

- The "Divine Dozen"
 - New/returning: CIGNA, Sierra, Tufts, Group Health (MN), Essence
 - Repeat rock stars: Kaiser, Martin's Point (ME/NH), Gunderson
- Six "Walking Dead," 3 eligible for termination end of 2016
- SNPs improved = HMOs/PPOs
- No rest for the weary: 4-Star plans in 2016 won't be in 2017



MEASURING NUANCES: CAHPS



2016 PART C STAR RATINGS MEASURES

	2016 Part C & D Star Ratings Measures					
2016				Improvement		
ID	2015 ID	Measure	Data Source	Measure	Weight	
C01	DMC22	Breast Cancer Screening	HEDIS	No	1	
C02	C01	Colorectal Cancer Screening	HEDIS	Yes	1	
C03	C04	Annual Flu Vaccine	CAHPS	Yes	1	
C04	C05	Improving or Maintaining Physical Health	HOS	No	3	
C05	C06	Improving or Maintaining Mental Health	HOS	No	3	
C06	C07	Monitoring Physical Activity	HEDIS / HOS	Yes	1	
C07	C08	Adult BMI Assessment	HEDIS	Yes	1	
C08	C09	Special Needs Plan (SNP) Care Management	Part C Plan Reporting	Yes	1	
C09	C10	Care for Older Adults – Medication Review	HEDIS	Yes	1	
C10	C11	Care for Older Adults – Functional Status Assessment	HEDIS	Yes	1	
C11	C12	Care for Older Adults – Pain Assessment	HEDIS	Yes	1	
C12	C13	Osteoporosis Management in Women who had a Fracture	HEDIS	Yes	1	
C13	C14	Diabetes Care – Eye Exam	HEDIS	Yes	1	
C14	C15	Diabetes Care – Kidney Disease Monitoring	HEDIS	Yes	1	
C15	C16	Diabetes Care – Blood Sugar Controlled	HEDIS	Yes	3	
C16	C18	Controlling Blood Pressure	HEDIS	Yes	3	
C17	C19	Rheumatoid Arthritis Management	HEDIS	Yes	1	
C18	C21	Reducing the Risk of Falling	HEDIS / HOS	Yes	1	
C19	C22	Plan All-Cause Readmissions	HEDIS	Yes	3	

2016 PART C STAR RATINGS MEASURES

2016 Part C & D Star Ratings Measures					
2016				Improvement	
ID	2015 ID	Measure	Data Source	Measure	Weight
C20	C23	Getting Needed Care	CAHPS	Yes	1.5
C21	C24	Getting Appointments and Care Quickly	CAHPS	Yes	1.5
C22	C25	Customer Service	CAHPS	Yes	1.5
C23	C26	Rating of Health Care Quality	CAHPS	Yes	1.5
C24	C27	Rating of Health Plan	CAHPS	Yes	1.5
C25	C28	Care Coordination	CAHPS	Yes	1.5
C26	C29	Complaints about the Health Plan	CTM	No	1.5
C27	C30	Members Choosing to Leave the Plan	Medicare Beneficiary Database Suite of	Yes	1.5
			Systems		
C28	DME08	Beneficiary Access and Performance Problems	CMS Administrative Data	No	1
C29	C31	Health Plan Quality Improvement	Star Ratings	No	5
C30	C32	Plan Makes Timely Decisions about Appeals	IRE	No	1.5
C31	C33	Reviewing Appeals Decisions	IRE	Yes	1.5
C32		Call Center – Foreign Language Interpreter and TTY Availability	Call Center	No	1.5


2016 PART D STAR RATINGS MEASURES

	2016 Part C & D Star Ratings Measures				
2016 ID	2015 ID	Measure	Data Source	Improvement Measure	Weight
D01		Call Center – Foreign Language Interpreter and TTY Availability	Call Center	No	1.5
D02	D01	Appeals Auto-Forward	IRE	Yes	1.5
D03	D02	Appeals Upheld	IRE	No	1.5
D04	D03	Complaints about the Drug Plan	CTM	No	1.5
D05	D04	Members Choosing to Leave the Plan	Medicare Beneficiary Database Suite of Systems	Yes	1.5
D06	DME08	Beneficiary Access and Performance Problems	CMS Administrative Data	No	1
D07	D05	Drug Plan Quality Improvement	Star Ratings	No	5
D08	D06	Rating of Drug Plan	CAHPS	Yes	1.5
D09	D07	Getting Needed Prescription Drugs	CAHPS	Yes	1.5
D10	D08	MPF Price Accuracy	PDE data, MPF Pricing Files, HPMS approved formulary extracts, and data from First DataBank and Medi-span	No	1
D11	D09	High Risk Medication	Prescription Drug Event (PDE) data	Yes	3
D12	D11	Medication Adherence for Diabetes Medications	Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; Common Working File (CWF)	Yes	3
D13	D12	Medication Adherence for Hypertension (RAS antagonists)	Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; Common Working File (CWF)	Yes	3
D14	D13	Medication Adherence for Cholesterol (Statins)	Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; Common Working File (CWF)	Yes	3
D15	DMD07	Medication Therapy Management Program Completion Rate for Comprehensive Medication Reviews	Part D Plan Reporting	No	1

WEAKNESS IN THE 2016 NUMBERS

2016 ID	Measure Description	2016 Avg Stars
D15	MTM Program Completion Rate for CMR	2.3
C12	Osteoporosis Management in Women With Fx	2.5
C08	Special Needs Plans (SNP) Care Management	2.5
C18	Reducing the Risk of Falling	2.7
C06	Monitoring Physical Activity	2.9
C13	Diabetes Care - Eye Exam	3.1
D03	Appeals Upheld	3.3
D08	Rating of Drug Plan	3.3
D09	Getting Needed Prescription Drugs	3.4

THE MEMBER EXPERIENCE: NOW HALF OF STARS



OPPORTUNITIES FOR NEW RETAIL PHARMACY COLLABORATION



- ★ Medication Adherence
- ★ High Risk Medications
- ★ Annual influenza vaccine
- ★ Care for older adults medication review, pain screening
- ★ Disease Management A1c control, controlling BP
- ★ RA, Osteoporosis management
- ★ Reducing fall risk

Evaluate opportunities for retail pharmacists to expand services to high-risk members through MTM-like programs and expanded services.

NEXT BIG THING IN MA AND PART D: VALUE-BASED INSURANCE DESIGN

MA/Part D VBID/MTM Demos

Rethinking formulary and benefit design

MTM gets real

Medicare Policy Changes

Aligning payment with medication optimization for the chronically ill

NEW NORMAL

Larger role for pharmacists as providers

Value-based approaches


MEDICARE ADVANTAGE VALUE-BASED INSURANCE DESIGN (MA-VBID)

The VBID model will test structuring benefits for individuals with certain conditions in ways expected to have the greatest potential to positively impact enrollee health relative to cost.

The model is scheduled to begin on January 1, 2017, and will have a 5-year test period.

All or a portion of that plan's service area is located within a test state.

MA-VBID STATES



Source: Centers for Medicare & Medicaid Services

MEMBER & PROVIDER ENGAGEMENT IMPROVE OUTCOMES

Medical Expense

Costs

Customize network (ACOs, PCMH, narrow network)

PCP attribution

Support services: transportation, DME, lab, home, counseling

Pay for Performance

Utilization

Engage members for wellness visits

Reduce cost sharing

Customize disease management programs

Maximize use of lower levels of care when appropriate

MEMBER & PROVIDER ENGAGEMENT IMPROVE OUTCOMES



Costs

Adjust formulary

Encourage mail order at preferred pharmacies

Utilization


Reduce cost-sharing

Customize disease management programs

Include medication management programs

CONCLUSIONS

- 1. Tailor best practices to a member panel
- Address social determinants first
- 3. Reduce cost sharing for specific drugs/classes
- 4. Exempt specific drugs/classes from cost sharing in coverage gaps
- 5. Reduce cost sharing for enrollees with chronic conditions
- 6. Incentivize members to participate in MTM
- 7. Create multi-tier cost sharing arrangements for high-value providers
- 8. Team-based proactivity is key
- 9. No innovation without collaboration
- 10. EVOLVE OR DIE.



JOHN GORMAN

Executive Chairman

- T 202.255.6924
- E jgorman@gormanhealthgroup.com

Gorman Health Group, LLC (GHG) is a leading consulting and software solutions firm specializing in government health programs, including Medicare managed care, Medicaid and Health Insurance Marketplace opportunities. For nearly 20 years, our unparalleled teams of subject-matter experts, former health plan executives and seasoned healthcare regulators have been providing strategic, operational, financial, and clinical services to the industry, across a full spectrum of business needs. Further, our software solutions have continued to place efficient and compliant operations within our client's reach.

GHG offers software to solve problems not addressed by enterprise systems. Our Valencia™ software reconciles membership of more than 10 million members in Medicare, Medicaid and the Health Insurance Marketplace. Over 3,000 compliance professionals use the Online Monitoring Tool™ (OMT), our complete Medicare Advantage and Part D compliance toolkit, while more than 25,000 brokers and sales agents are certified and credentialed using Sales Sentinel™. In addition, hundreds of health care professionals are trained each year using Gorman University™ training courses.

We are your partner in **government-sponsored health programs**